Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia-Reference-Cited by-同舟云学术

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Published:2013-04-30 Issue:15 Volume:119 Page:2728-2736
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop¹,Thomas Deborah¹,Jorgensen Jeffrey²,Kebriaei Partow³,Jabbour Elias¹,Rytting Michael¹,York Sergernne¹,Ravandi Farhad¹,Garris Rebecca¹,Kwari Monica¹,Faderl Stefan¹,Cortes Jorge¹,Champlin Richard³,O'Brien Susan¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Hematopathology; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Cellular Therapy and Stem Cell Transplantation; The University of Texas MD Anderson Cancer Center; Houston Texas

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28136/fullpdf

Reference14 articles.

1. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL);Gokbuget;Hematol Oncol Clin North Am.,2000

2. Modern therapy of acute lymphoblastic leukemia;Bassan;J Clin Oncol.,2011

3. Adult acute lymphoblastic leukemia;Faderl;Cancer.,2010

4. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia;Thomas;Cancer.,2006

5. Rituximab in the treatment of adult ALL;Gokbuget;Ann Hematol.,2006

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

2. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

3. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL;Blood Advances;2024-06-14

4. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions;Journal of Hematology & Oncology;2024-05-11

5. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults;Critical Reviews in Oncology/Hematology;2024-04